HealthCare Global Enterprises Ltd approved a further investment of up to ₹16 crore in HCG Rajkot Hospitals LLP, its wholly owned subsidiary, during a Board meeting held on August 6, 2026. The capital injection aims to strengthen the subsidiary’s balance sheet through repayment of dues and provision of working capital, ensuring operational continuity for the cancer-specialty facility in Gujarat. This strategic allocation underscores the parent company’s commitment to sustaining its regional oncology network amidst ongoing expansion efforts.

The transaction was sanctioned under Regulation 30(2) and (6) read with Schedule III Part A Para A sub-para (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026, issued on July 11, 2023, and last updated on January 30, 2026. As HCG Rajkot is a wholly owned subsidiary, the investment qualifies as a related party transaction executed on an arm’s length basis. No promoter or group company holds an interest in the entity beyond the Company’s 100% ownership.

Investment Details

The proposed outlay involves a cash consideration of up to ₹16 crore. HealthCare Global Enterprises will retain 100% control of HCG Rajkot post-investment. The company has set a deadline of September 30, 2026, for the completion of this transaction. No governmental or regulatory approvals are required for this internal capital reallocation.

Subsidiary Performance Context

HCG Rajkot operates a cancer-specialty hospital in Rajkot, Gujarat, with a licensed capacity of 147 beds, of which 134 are currently operational. Incorporated on September 22, 2017, the facility has demonstrated consistent revenue growth over the past three fiscal years.

What the Numbers Show

The subsidiary’s revenue rose to ₹60.67 crore in FY26, marking a notable acceleration from the modest growth seen between FY24 and FY25. While FY25 saw a marginal increase of approximately ₹0.12 crore over FY24, FY26 delivered a jump of roughly ₹5.18 crore. This recent uptick suggests improving utilization or pricing power at the Rajkot facility, justifying the parent company’s decision to inject fresh capital for working capital needs rather than merely covering losses.

Healthcare Global Enterprises Limited’s subsidiary, HCG Manavata Oncology LLP, has entered into an agreement to acquire a 26% equity stake in Epic Vighnaharta Renewable Energy Private Limited (EVRE) for ₹38 lakh. This strategic move allows the oncology provider to secure captive power supply from a new renewable energy source, aligning with operational sustainability goals while diversifying into clean energy infrastructure through its subsidiary structure.

The transaction was disclosed on August 04, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The filing confirms that the deal does not constitute a related-party transaction, as neither the promoter group nor other group companies hold direct interests in EVRE beyond the indirect stake held via the LLP.

Transaction Structure

The acquisition involves the subscription of 3,80,000 equity shares of ₹10 each, representing 26% of EVRE’s total share capital on a fully diluted basis. The entire consideration of ₹38 lakh is structured as a cash payment. Upon completion, HCG Manavata Oncology LLP will hold the minority stake directly, giving Healthcare Global Enterprises Limited an indirect interest of up to 26% in the renewable energy developer.

Strategic Rationale

EVRE is primarily engaged in power generation from renewable sources and is currently developing a solar power plant in Mangalwedha, District Solapur, Maharashtra. The facility is designed with an initial capacity of 1.3 MWp. By acquiring this stake, HCG Manavata Oncology LLP qualifies as a captive user of the plant, enabling EVRE to supply generated electricity directly to the LLP for its own consumption. This arrangement supports the company’s infrastructure needs while participating in the clean energy development sector.

Target Company Profile

Epic Vighnaharta Renewable Energy Private Limited was incorporated on March 22, 2025, under the Companies Act, 2013. Its registered office is located in Mumbai. As a newly established entity focused on project development, EVRE reported nil revenue from operations for FY26, FY25, and FY24. The company’s authorized share capital stands at ₹1,00,000. No specific governmental approvals are required for the incorporation or this acquisition, aside from standard business licenses.

What the Numbers Show

The acquisition highlights a shift toward vertical integration in utility costs for Healthcare Global Enterprises. While the financial outlay of ₹38 lakh is modest relative to the parent company’s scale, the strategic value lies in securing long-term captive power supply. With EVRE reporting no historical revenue, the investment is purely forward-looking, tied to the commissioning of the 1.3 MWp solar plant. This structure minimizes immediate financial risk while locking in potential energy cost savings and sustainability credits for the oncology network.